Retatrutide Research Overview: Triple Agonist GLP-1/GIP/Glucagon for Weight Loss
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that simultaneously activates three receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonist mechanism distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP), positioning it as the most potent weight loss peptide yet studied in clinical trials.
Mechanism of Action
GLP-1 receptor agonism: Like semaglutide and tirzepatide, retatrutide activates GLP-1 receptors in the hypothalamus (appetite suppression), pancreas (insulin secretion), stomach (gastric emptying delay), and liver (glucagon suppression).
GIP receptor agonism: GIP receptor activation enhances insulin secretion in a glucose-dependent manner and may improve GLP-1 receptor sensitivity. The GIP component is shared with tirzepatide.
Glucagon receptor agonism: The addition of glucagon receptor activation is the key differentiator. Glucagon receptor agonism increases energy expenditure (thermogenesis), enhances hepatic fat oxidation, and promotes lipolysis. This mechanism directly targets fat burning rather than just reducing caloric intake.
Phase 2 Clinical Trial Results
The landmark Phase 2 trial of retatrutide was published in the New England Journal of Medicine in 2023. Key findings:
| Dose | Weight Loss at 48 Weeks | |------|------------------------| | 1 mg | -8.7% | | 4 mg | -17.3% | | 8 mg | -22.8% | | 12 mg | -24.2% | | Placebo | -2.1% |
The 24.2% mean weight loss at the highest dose represents the greatest weight reduction ever observed in a clinical trial of a pharmacological agent at 48 weeks.
Comparison with Other GLP-1 Class Agents
| Agent | Receptors | Peak Weight Loss (Clinical Trials) | |-------|----------|-----------------------------------| | Semaglutide (Ozempic/Wegovy) | GLP-1 | ~15% (STEP trials) | | Tirzepatide (Mounjaro/Zepbound) | GLP-1 + GIP | ~22% (SURMOUNT trials) | | Retatrutide | GLP-1 + GIP + Glucagon | ~24% (Phase 2) |
Metabolic Effects Beyond Weight Loss
Liver fat reduction: The glucagon receptor component drives significant hepatic fat reduction, making retatrutide a promising research tool for NAFLD/NASH.
Triglycerides: Phase 2 data showed significant reductions in triglycerides (up to -42% at the highest dose).
Blood pressure: Retatrutide produced clinically meaningful reductions in systolic blood pressure.
Insulin resistance: Significant improvements in HOMA-IR (insulin resistance marker) were observed.
Development Status
Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program) for obesity and type 2 diabetes. Phase 3 results are expected in 2025-2026. It has not yet received FDA approval.
Summary
Retatrutide represents the next frontier in GLP-1 class pharmacology. Its triple agonist mechanism — combining appetite suppression (GLP-1), insulin sensitization (GIP), and thermogenesis/fat oxidation (glucagon) — produced the highest weight loss ever observed in a pharmacological clinical trial. It is a critical research tool for understanding the additive and synergistic effects of incretin and glucagon receptor co-activation.
See Also: Tirzepatide vs. Semaglutide: Which Should Researchers Study? | GLP-1 Receptor Agonism: Mechanism of Action Deep Dive
Shop Research Grade: View Retatrutide Research Grade →
Was this article helpful?
Click a star to rate